Authors: Amaia Rodriguez,; Victoria Catalan,; Javier Gomez-Ambrosi,; Gema Fruhbeck,

Source: Current Pharmaceutical Design, Volume 13, Number 21, July 2007 , pp. 2169-2175(7)

Publisher: Bentham Science Publishers

Abstract:

The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upperbody obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed “adipokines”). Weight reduction and increased physical activity represent the main approach to tackle the “diabesity” epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.

Keywords: Cathecolamines; stimulatory GTP-binding protein; free fatty acids; Natriuretic peptides; lipolysis; Adiponectin

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138161207781039599

Affiliations: 1: Dept. of Endocrinology,Clinica Universitaria de Navarra, Avda. Pio XII 36, 31008-Pamplona,SPAIN.

Publication date: 2007-07-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Amaia Rodriguez, ;  Victoria Catalan, ;  Javier Gomez-Ambrosi, ;  Gema Fruhbeck,

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers